Category: Validation

This category can only be viewed by members. To view this category, sign up by purchasing MEMBER PLUS +.

Risk Management of Biopharma Operations Over Lifecycle – An ICH Q12 Overview

Presented by: Dr. José C. Menezes, CSO, ValGenesis Join us for a webinar where we’ll delve into the practical application of ICH Q12 principles for biopharma operations. Biotech processes prior to QbD use control strategies that lack understanding of criticality and definition of CPPs or CQAs. Discover how to define these parameters from manufacturing history, […]

To access this post, you must purchase MEMBER PLUS +.

Read More »

Cleaning Validation Equipment Grouping

Created by: Fred Ohsiek, Cleaning Validation Expert Grouping equipment for cleaning validation is a common practice for reducing execution, resources, and production downtime.  Though regulatory [1] [2] and industry guidelines [3] support the practice and provide guidance, there is a clear requirement for scientific justification. Common industry practice is to either avoid grouping because of […]

To access this post, you must purchase MEMBER PLUS +.

Read More »

Stage 1: High-Potent Active Pharmaceutical Ingredient (HPAPI) Cleaning Validation (CV)

Created by: Fred Ohsiek, Cleaning Validation Expert This article not only applies to high potent (HP) active pharmaceutical ingredient (API) manufacturing, but it also includes pharmaceutical manufacturing products with HP APIs; therefore, the term “HPAPI manufacturing” and “HPAPI product” applies to both types of production. It is important that the requirements for the finished manufacturing […]

To access this post, you must purchase MEMBER PLUS +.

Read More »

Improving Risk-Based Decision Making Effectiveness: Insights From Other Industries

Created by: Valerie Mulholland, Senior Director / Principle Consultant, GMP Services Ltd & Anne Greene, Director PRST, Technological University, Dublin The Pharmaceutical Regulatory Science Team (PRST), founded in 2005, carries out research into strategies to address the challenges and opportunities of implementing science and risk-based decision making and manufacturing approaches. Since its inception, the PRST […]

To access this post, you must purchase MEMBER PLUS +.

Read More »

Improving Risk-Based Decision Effectiveness: A Case For Risk Decision Review Points (KDRPS) In the Quality Risk Management Process

Created by: Valerie Mulholland, Senior Director / Principle Consultant, GMP Services Ltd & Anne Greene, Director PRST, Technological University, Dublin The Pharmaceutical Regulatory Science Team (PRST), founded in 2005, carries out research into strategies to address the challenges and opportunities of implementing science and risk-based decision making and manufacturing approaches. Since its inception, the PRST […]

To access this post, you must purchase MEMBER PLUS +.

Read More »